GlassScriptPhysician profile
Treasa Davis
NPI 1336467620
$1,938.28
in general payments reported to CMS, 2019-2025
29 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $233 · 2021: $273 · 2022: $321 · 2023: $183 · 2024: $377 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $287.24 | 2021-2025 | Ubrelvy |
| Merck Sharp & Dohme LLC | $230.12 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Optinose US, INC. | $146.95 | 2019-2023 | |
| Astellas Pharma US INC | $132.73 | 2024 | Veozah |
| Shockwave Medical, INC | $125.89 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $125.67 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $99.48 | 2023-2025 | Ozempic, Saxenda, Wegovy |
| Gilead Sciences, INC. | $93.22 | 2019-2021 | |
| Exact Sciences Corporation | $83.74 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $77.91 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $48.94 | 2021 | |
| Esperion Therapeutics, INC. | $48.94 | 2020-2022 | |
| Axsome Therapeutics, INC. | $47.86 | 2025 | Auvelity |
| Sage Therapeutics, LLC | $47.77 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $38.03 | 2022-2023 | Twirla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $36.00 | 2021 | |
| Phadia US INC. | $30.35 | 2019-2020 | |
| Allergan, INC. | $27.27 | 2020 | |
| Boston Scientific Corporation | $22.83 | 2022 | |
| Lilly USA, LLC | $22.09 | 2024 | Zepbound |
| Hikma Pharmaceuticals USA | $21.82 | 2024 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $21.35 | 2021 | |
| Abbott Laboratories | $20.82 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.56 | 2025 | Zoryve |
| Therapeuticsmd, INC. | $19.91 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.23 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $16.81 | 2021 | |
| Pfizer INC. | $13.63 | 2020 | |
| Glaxosmithkline, LLC. | $13.12 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Treasa Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.